TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06161714
Drug: Lidocaine 2%/Epi 1:100000 Inj Cart 1.7Ml
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% Lidocaine with 1:100,000 epinephrine buccal infiltration
Study: NCT04727736
Drug: 18F-DCFPyL
Normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
Study: NCT04464967
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
Study: NCT04464967
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
Study: NCT04993872
Drug: Biktarvy Tab
Normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Multicenter Pilot study aiming to assess the safe use of BIC/FTC/TAF in HIV-KTR, using a single-arm design.
Study: NCT05964985
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
Study: NCT05964985
Drug: Compound lidocaine
Normalized name: BENZOIN COMPOUND
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side
Study: NCT05964985
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral quadratus lumborum block
Study: NCT05477004
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A multi-day continuous ketamine infusion delivered intravenously at subanesthetic doses in a monitored setting
Study: NCT05587894
Drug: Paxlovid 5 days
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally.~Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.~Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
Study: NCT05587894
Drug: Paxlovid 10 days
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
Study: NCT05587894
Drug: Veklury
Normalized name: Veklury
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir flash, 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.
Study: NCT04655508
Drug: Seretide
Normalized name: seractide
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For children between 6 to 11 years (\< 12 years): 50 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 50/25) :two puffs twice a day from randomisation during 6 months using inhalation chamber~- For children between 12 to 17 years (\> or = 12 years) : 125 μg inhaled fluticasone propionate and 25 μg salmeterol (SERETIDE® 125/25): two puffs twice a day from randomisation during 6 months using inhalation chamber
Study: NCT04531748
Drug: Toremifene
Normalized name: Toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
Study: NCT05184348
Drug: Acitretin group
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose of 0.5-1 mg per kg per day orally for 3 month.
Study: NCT05128591
Drug: Rivaroxaban 18mg Oral Tablet
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AD-109 (Rivaroxaban 18mg) Oral Tablet
Study: NCT05128591
Drug: Rivaroxaban 20 MG Oral Tablet
Normalized name: rivaroxaban 20 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AD-1091 (Rivaroxaban 20mg) Oral Tablet
Study: NCT05305859
Drug: venetoclax combining chidamide and azacitidine (VCA)
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: information already included in arm/group descriptions
Study: NCT05324449
Drug: Cannabidiol 100 MG/ML
Normalized name: cannabidiol 100 MG/ML
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pharmaceutical grade cannabidiol
Study: NCT00002071
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04373317
Drug: Pimavanserin
Normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed-dose Pimavanserin - Pimavanserin is a new antipsychotic agent, and pure 5HT-2A inverse agonist, that was approved by the FDA recently (2016) for the treatment of PDP. It is the only FDA-approved medication for PDP, but is still not the first-line AP used in PD. All participants assigned to pimavanserin will receive the FDA-approved dose of 34 mg (equivalent to 40 mg pimavanserin tartrate) daily without titration up or down; however, because pimavanserin is blinded to quetiapine, participants will undergo sham titration based on tolerability (i.e., overall adverse event profile) and efficacy (i.e., improvement in severity of psychosis).
Study: NCT04373317
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible-dose Quetiapine - Quetiapine, which is a mixed serotonin and dopamine receptor antagonist, is by far the most commonly used AP for PDP. However, scientific evidence for the efficacy of quetiapine in PDP is almost non-existent as most of the studies were underpowered, had high drop-out rates, and possibly underdosed quetiapine. Quetiapine immediate and extended release will be titrated as shown:~Baseline visit Quetiapine: 25 mg IR QHS, All participants must be up-titrated to 50 mg/day Pimavanserin: 34 mg QHS~Week 1 call Quetiapine: 50 mg XR QHS, Up-titration to 50 mg Pimavanserin: 34 mg QHS~Week 3 visit Quetiapine: 100 mg XR QHS, Up-titration as appropriate Pimavanserin: 34 mg QHS~Week 5 visit Quetiapine: 150 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS~Week 6 call Quetiapine: 200 mg XR QHS, Up- or down-titration as appropriate Pimavanserin: 34 mg QHS
Study: NCT06470451
Drug: Hypericin
Normalized name: Hypericin
DrugBank: Hypericin (DB13014)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
Study: NCT00002347
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002295
Drug: Inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002347
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002347
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06491680
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.~taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose.
Study: NCT00002347
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04322669
Drug: Pidotimod
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized in ratio of 1:1 to receive Pidotimod 400 milligrams (mg), once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
Study: NCT05559164
Drug: Lipitor 40mg Tablet
Normalized name: Lipitor 40mg Tablet
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food
Study: NCT06613191
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will be on aspirin alone or P2Y12 inhibitor alone
Study: NCT06613191
Drug: P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will be taking either P2Y12 inhibitor at time of colonoscopy
Study: NCT05449444
Drug: Masitinib 4.5 mg/kg/day
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib 4.5 mg/kg/day
Study: NCT05449444
Drug: Masitinib 6.0 mg/kg/day
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib 6.0 mg/kg/day
Study: NCT06487715
Drug: albumin-bound paclitaxel (260 mg/m2, d1)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 260 mg/m2, d1)
Study: NCT06487715
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 80 mg/m2, d1-14
Study: NCT06487715
Drug: sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg, d1
Study: NCT06487715
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2
Study: NCT06101134
Drug: relatlimab+nivolumab
Normalized name: nivolumab / relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06101134
Drug: relatlimab+nivolumab+rHuPH20
Normalized name: nivolumab / relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06101134
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06101134
Drug: nivolumab+rHuPH20
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT00002388
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05897372
Drug: ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care for diabetic kidney disease.
Study: NCT05413915
Drug: Asciminib
Normalized name: Asciminib
DrugBank: Asciminib (DB12597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tyrosine kinase inhibitor
Study: NCT05413915
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tyrosine kinase inhibitor
Study: NCT05672316
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04677114
Drug: Buprenorphine and Outpatient Parenteral Antibiotic Therapy
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be complete IV antibiotics with OPAT. All participants will receive buprenorphine treatment of OUD.
Study: NCT04677114
Drug: Buprenorphine and standard of care antibiotic treatment
Normalized name: combinations of different antibiotics
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will receive treatment of OUD and the infection per usual clinical care.
Study: NCT04643327
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.
Study: NCT05118737
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
Study: NCT05742256
Drug: Oxycodone 1mg/kg
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml
Study: NCT05742256
Drug: Oxycodone 1.5mg/kg
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test group 2 (OCB group): oxycodone 1.5mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml.
Study: NCT05219409
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dose of sitagliptin will be established on the basis of the estimated glomerular filtrate: 100 mg in single daily administration (estimated glomerular filtration rate less than or equal to 45 mL / min / 1.73 m2) or 50 mg (estimated glomerular filtration rate 30-45 mL / min / 1.73 m2)
Study: NCT05183334
Drug: Sildenafil 50 mg
Normalized name: sildenafil 50 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PD5I
Study: NCT05183334
Drug: Tramadol Hydrochloride 100 MG
Normalized name: tramadol hydrochloride 100 MG
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: opiod
Study: NCT05074134
Drug: [14C]-TNP-2092
DrugBank: TNP-2092 (DB16312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single intravenous (IV) dose of 300 mg/3 µCi \[14C\]-TNP-2092 administered over 60 minutes (± 10 minutes).
Study: NCT05136677
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05136677
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05136677
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05701540
Drug: Tegoprazan
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50mg tablet
Study: NCT05701540
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20mg tablet~1. For patients with ERD: two Esomeprazole 20mg tablets~2. For patients with NERD: one Esomeprazole 20mg tablet
Study: NCT05063578
Drug: Lidocaine 2% Injectable Solution
Normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
Study: NCT03941587
Drug: Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25Joule/cm2
Study: NCT03941587
Drug: Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
Study: NCT04978337
Drug: Rilematovir
Normalized name: Rilematovir
DrugBank: Rilematovir (DB15672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilematovir 250 mg will be administered orally.
Study: NCT01089166
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04983810
Drug: Fadraciclib
Normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadraciclib is a highly selective, orally- and intravenously- available, 2nd generation amino-purine inhibitor of CDK2 and CDK9.
Study: NCT02942706
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-EGFR monoclonal antibody
Study: NCT05886088
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active comparator
Study: NCT05886088
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active comparator
Study: NCT05307679
Drug: Basmisanil
Normalized name: Basmisanil
DrugBank: Basmisanil (DB11877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral basmisanil at age-appropriate dosages
Study: NCT06355037
Drug: Quercetin
Normalized name: Quercetin
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: quercetin 1000mg d1-d3, qw
Study: NCT06355037
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib 50mg d1-d3, qw
Study: NCT06355037
Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
Study: NCT06611657
Drug: Antirotinib hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral antirotinib treatment was started 2 weeks before radiotherapy for brain metastases, stopped for 1 week after 2 weeks, and continued after radiotherapy until tumor progression
Study: NCT05943470
Drug: Icodextrin Peritoneal Dialysis Solution
Normalized name: Icodextrin Peritoneal Dialysis Solution
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alternative day use of icodextrin comparing with daily use of icodextrin
Study: NCT06720285
Drug: General anesthesia and opioids (fentanyl, propofol, rocuronium)
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Compared to experimental arm, the active comparator arm received the same procedure except in the analgesia maintenance which was performed through continuous fentanyl infusion. However, during craniotomy surgery, pain may occur in patients in any arms. This was defined as a sudden rise of heart rate and blood pressure higher than 20% from baseline. In that case, a bolus of fentanyl was administered as rescue analgesia.
Study: NCT00002314
Drug: Ro 24-7429
Normalized name: Ro 24-7429
DrugBank: Ro 24-7429 (DB16062)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06721585
Drug: Tecovirimat Oral Capsule [Tpoxx]
Normalized name: tecovirimat Oral Capsule [Tpoxx]
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tecovirimat Oral Capsule 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)
Study: NCT05582278
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg
Study: NCT05582278
Drug: tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tislelizumab 200 mg, every 3 weeks.
Study: NCT04305028
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet
Study: NCT04305028
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 75-100 mg once daily, tablet
Study: NCT06720506
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine will given IV as shot in Dose 1mg /kg
Study: NCT05454020
Drug: XG004
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XG004 gel in two concentrations (5% and 10%) will be applied topically once-daily, twice-daily or three times daily in a designated area of the study knee.
Study: NCT06721195
Drug: Remimazolam for Gastrointestinal Endoscopy Sedation
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This intervention involves the use of remimazolam, a short-acting benzodiazepine, for sedation during gastrointestinal endoscopy procedures (gastroscopy, colonoscopy, or both). Remimazolam is administered intravenously at an initial dose of 0.2-0.3 mg/kg, followed by additional doses of 2.5 mg as needed to maintain adequate sedation (MOAA/S score ≤ 2).~Unlike other benzodiazepines, remimazolam is rapidly metabolized by plasma esterases, resulting in a quick onset and recovery with minimal respiratory and cardiovascular depression. The study specifically evaluates the euphoria-inducing potential of remimazolam, using the ARCI-MBG scale pre- and post-procedure to assess its effect on patient comfort and satisfaction.
Study: NCT05987826
Drug: Furmonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furmonertinib 80mg QD oral 8 weeks.
Study: NCT00767286
Drug: flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00767286
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no